Today: 9 June 2026
Ashtead (AHT.L) shares slide 3% as buyback update lands into Powell-probe market jitters
12 January 2026
1 min read

Ashtead (AHT.L) shares slide 3% as buyback update lands into Powell-probe market jitters

LONDON, Jan 12, 2026, 09:11 GMT — Regular session.

  • Ashtead shares slipped 3.1% in early London trading, underperforming a weaker FTSE 100
  • The firm revealed an additional tranche of share buybacks as part of its $1.5 billion programme
  • After Powell’s DOJ subpoena revelation shook risk appetite, investors are now focused on Tuesday’s U.S. CPI data

Ashtead Group plc shares dropped 3.1% to 5,420 pence by 0910 GMT, adding to a volatile start for cyclicals as investors digested a new buyback update amid a shaky macroeconomic environment.

Sentiment shifted to cautious territory after U.S. Federal Reserve Chair Jerome Powell revealed that the Justice Department had issued grand jury subpoenas and threatened a criminal indictment tied to his previous testimony, reigniting concerns over central bank independence.

This is crucial for Ashtead, given that the bulk of its profits come from the U.S., where equipment rental relies heavily on construction activity and borrowing costs. The next key data points are just around the corner: U.S. December CPI on Tuesday, followed by UK GDP figures for November on Thursday.

Ashtead reported purchasing 69,600 shares for its treasury on Jan. 9, at an average price of 5,556.0171 pence per share, with J.P. Morgan Securities plc acting as broker, according to a filing. The company stated it currently has 416,524,197 shares outstanding, excluding treasury shares.

When a company buys shares into treasury, it keeps them instead of leaving them circulating publicly. This reduces the effective share count and can boost earnings per share over time. However, it doesn’t directly affect equipment demand or pricing.

Ashtead’s buyback plan, capped at $1.5 billion, is set to kick off on March 2, 2026. The initial purchases will take place on the London Stock Exchange, then move to New York as the company advances its U.S.-centered listing strategy.

Ashtead warned that higher U.S. internal repair expenses and reduced hurricane activity hit its half-year profit, while confirming its shareholder return strategy and maintaining its outlook.

Monday brought no fresh trading update aside from the buyback announcement, so the shares moved largely in line with wider risk sentiment and interest rate expectations.

The risk for bulls is clear: a hotter-than-expected CPI reading could drive yields higher and derail rate-cut expectations, squeezing valuations on economically sensitive stocks. A cooler print might relieve some pressure, but Powell’s remarks add fresh headline uncertainty.

The FTSE 100 edged down in early trading, with Ashtead falling more sharply than the index.

“One headline shifts focus to governance, oversight, and politics,” Charu Chanana, chief investment strategist at Saxo Bank, wrote, noting it compels investors to factor in an “institutional risk premium.” Reuters

On Sunday, Powell described the move as “unprecedented.” Markets are now on edge, waiting to see if there will be any legal or political fallout before Tuesday’s U.S. inflation report. federalreserve.gov

Stock Market Today

  • S&P 500 Rallies on Chipmaker Gains; Crude Oil Prices Retreat After Iran-Israel Ceasefire Signal
    June 9, 2026, 9:24 AM EDT. The S&P 500 gained +0.30% on Monday, driven by renewed investor interest in artificial intelligence boosting chipmakers. Nasdaq 100 rose +1.58%, while the Dow slipped -0.16%, dragged lower by Apple's -1% drop amid lukewarm AI platform feedback. Crude oil prices surged over +4% initially due to Iran-Israel tensions but retreated after Iran signaled an end to its current military operation. The market discounts a low 3% chance of a +25 basis point rate hike by the Federal Reserve on June 16-17. Treasury yields climbed, with 10-year notes reaching a two-week high of 4.58%, pressured by strong US jobs data and heavy upcoming Treasury auctions. Overseas markets closed mixed, with China's Shanghai Composite down -1.70% and Japan's Nikkei falling -3.85%.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
National Grid plc stock drops today as markets wobble; dividend clock ticks on NG.L
Previous Story

National Grid plc stock drops today as markets wobble; dividend clock ticks on NG.L

Silver price stock SLV jumps nearly 7% as Fed probe headlines push silver to fresh records
Next Story

Silver price stock SLV jumps nearly 7% as Fed probe headlines push silver to fresh records

Go toTop